For Evaporator A/C 1994-2004 H987JW 2001 1999 2000 1996 2002 2003 1997 S10 Chevy Car & Truck Condensers & Evaporators


  1. Home
  2. For Evaporator A/C 1994-2004 H987JW 2001 1999 2000 1996 2002 2003 1997 S10 Chevy
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
A/C Evaporator For 1994-2004 Chevy S10 1997 2003 2002 1996 2000 1999 2001 H987JW
Condition: New Brand:

Four Seasons

Application: Chevrolet S10 A/C Evaporator Part Number: H987JW
Product Name: A/C Evaporator Warranty: 12 Month Warranty
Product Name 2: A/C Evaporator Core Notes: Evaporator Core -- Evaporator replacement for this application...
CS-SKU: 400:H987JW Years: 1997 2003 2002 1996 2000 1999 1994 2001 1998 1995 2004
published on tue nov 09 2021

For Evaporator A/C 1994-2004 H987JW 2001 1999 2000 1996 2002 2003 1997 S10 Chevy Car & Truck Condensers & Evaporators

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

For Evaporator A/C 1994-2004 H987JW 2001 1999 2000 1996 2002 2003 1997 S10 Chevy Car & Truck Condensers & Evaporators

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS